article thumbnail

Sanofi stands behind 'accuracy of our accounts' amid reports of French manipulation probe

Fierce Pharma

Since launching the Regeneron-partnered antibody Dupixent in 2017, Sanofi has relied on the star medicine for sales growth.

Medicine 220
article thumbnail

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Fierce Pharma

Since 2017, the company has sold off three PRVs—getting less in return for each successive sale. The most recent sale came Wednesday as Sarepta revealed a $102 million deal for its PRV which came along with the FDA’s endorsement of Duchenne muscular dystrophy treatment Elevidys. Just ask Sarepta Therapeutics. |

FDA 234
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The 10 Blog Posts Sales Leaders Found Most Helpful in 2017

The Brooks Group

With many clients and prospects out of the office, however, there are opportunities for your entire sales team to assess what’s going well and where there’s room for improvement. Make the most of any downtime your team has this month to focus on improving sales effectiveness to hit the ground running in the New Year.

Sales 61
article thumbnail

B2B Sales Prospecting: What You Need To Know

Spotio

However, B2B sales prospecting strategy is not as easy as it sounds. B2B sales prospecting is the process of evaluating leads and prospective customers as potential sources of new business. This is why you may need to adjust your B2B sales prospecting techniques. The B2B Buyer Journey The B2B buying experience has changed.

article thumbnail

2017 in Review – Birthdays, Gong Ringing, and the Future of Sales Training

The Brooks Group

2017 was a big year for The Brooks Group. Since then, we’ve delivered training to over one million sales professionals, in over 350 industries, in 22 countries around the world. Every day we pay tribute to Bill by helping our clients and their sales teams achieve their full potential in sales excellence.

article thumbnail

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

Research shows that the three-drug companies that dominate global insulin sales — Novo Nordisk, Eli Lilly, and Sanofi may not be entirely to blame for the soaring costs to people with diabetes. The report showed that the PBM gross profit increased from $25 billion to $28 billion between 2017 and 2019. Los Angeles Times. billion to $5.7

Insurance 240
article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Sales 52